Approach to and Treatment of Goiters

Medical Clinics of North America

Volumn 96, Issue 2, 2012, Pages 351-368

  Medeiros Neto, Geraldo ^a   Camargo, Rosalinda Y ^a   Tomimori, Eduardo K ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

L thyroxine therapy; Multinodular goiter; Radioiodine ablation; Simple goiter; Sonography; Surgery

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CORTICOSTEROID; INSULIN I 131; IODINE; LEVOTHYROXINE; LINAMARIN; LIOTHYRONINE; RETINOL; THIAMAZOLE; THIOCYANATE; THYROID PEROXIDASE; THYROTROPIN; THYROXINE; ZINC;

ASPIRATION BIOPSY; AUTOIMMUNE DISEASE; BLEEDING; BRASSICA; CASSAVA; CHILD NUTRITION; CHROMOSOME; COMPUTER ASSISTED TOMOGRAPHY; CYTOLOGY; DIETARY INTAKE; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; ECHOGRAPHY; ENDEMIC GOITER; ENVIRONMENTAL FACTOR; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GOITER; HEART ARRHYTHMIA; HEART DISEASE; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; IODINE DEFICIENCY; MALNUTRITION; MUTAGENESIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PALPATION; PEARL MILLET; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SCINTIGRAPHY; SEX DIFFERENCE; SIMPLE DIFFUSE GOITER; SMOKING; SOYBEAN; SPONGE (PORIFERA); THYROID CELL; THYROID GLAND; THYROID HORMONE SYNTHESIS; THYROID WEIGHT; THYROIDECTOMY; THYROTROPIN RELEASE; TOXIC GOITER; TRACHEA COMPRESSION; URINARY EXCRETION;

COMBINED MODALITY THERAPY; GOITER; GOITER, NODULAR; HUMANS; IODINE RADIOISOTOPES; RISK FACTORS; THYROIDECTOMY; THYROTROPIN; THYROXINE;

EID: 84858761169     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2012.01.010     Document Type: Review

References (83)

1. Merke F. History and iconography of endemic goiter and endemic cretinism 1974, Verlag Hans Huber, Stuttgart and Wien, [in German].
2. Medeiros-Neto G., Sawin C.T. Francisco Freire-Alemão (1797-1874) and the early study of endemic goiter in Brazil. Endocrinologist 1996, 6:353-355.
3. Zimmermann M.B., Jooste P.L., Pandav C.S. Iodine deficiency disorders. Lancet 2008, 372:1251-1262.
4. Delange F., Benker G., Caron P., et al. Thyroid volume and urinary iodine in European schoolchildren; standardization values for assessment of iodine deficiency. Eur J Endocrinol 1997, 136:180-187.
5. Hegedus L., Bonnema S.J., Bennedbaek F.N. Management of simple nodular goiter: current status and future perspectives. Endocr Rev 2003, 24:102-132.
6. Medeiros-Neto G, Henneman G: Multimodular goiter. Available at: 2010. Accessed November 7, 2011. http://www.thyroidmanager.org.
7. Turbridge W.M., Evered D.C., Hall R., et al. The spectrum of thyroid disease in a community: the Wickham survey. Clin Endocrinol 1977, 7:481-493.
8. Vander J.B., Gastón E.A., Dawber T.R. Significance of solitary nontoxic nodules. preliminary report. N Engl J Med 1954, 251:970-976.
9. Berghout A., Wiersinga W.M., Smits N.J., et al. Interrelationships between age, thyroid volume, thyroid nodularity and thyroid function in patients with sporadic non-toxic goiters. Am J Med 1995, 89:602-608.
10. Hegedus L., Paschke R., Krohn K., et al. Multinodular goiter. Endocrinology 2010, 1636-1649. Saunders-Elsevier, Philadelphia. 6th edition. J.L. Jamenson, L.J. Degroot (Eds.).
11. Bahn R.S., Castro M.R. Approach to the patient with non-toxic multinodular goiter. J Clin Endocrinol Metab 2011, 96:1202-1212.
12. Hegedus L., Brix T.H., Paschke R. Etiology of simple goiter. Thyroid 2009, 19:209-211.
13. Krohn K., Wohlgenuth S., Gerber H., et al. Hot microscopic areas of iodine deficient thyroid goiters contain constitutively TSH-receptor mutations. J Pathol 2000, 192:37-42.
14. Studer H., Peter H.J., Gerber H. Natural heterogeneity of thyroid cells: the basis for understanding thyroid function and nodular growth. Endocr Rev 1989, 10:125-134.
15. Gaitan E., Cooksey R.C., Legan J., et al. Antithyroid and goitrogenic effects of coal-water extracts from iodine-sufficient goiter areas. Thyroid 1993, 3:49-53.
16. Ngudi D.D., Kuo Y.H., Lambein F. Cassava cyanogens and free amino acids in raw and cooked leaves. Food Chem Toxicol 2003, 41:1193-1197.
17. Gaitan E., Cooksey R.C., Legan J., et al. Antithyroid effects in vivo and in vitro of babassu and mandioca: a staple food in goiter areas of Brazil. Eur J Endocrinol 1994, 131:138-144.
18. Schröder-van der Elst J.P., Smit J.W., Romijn H.A., et al. Dietary flavonoids and iodine metabolism. Biofactors 2003, 19:171-176.
19. Doerge D.R., Chang H.C. Inactivation of thyroid peroxidase by soy isoflavones, in vitro and in vivo. J Chromatogr B Analyt Technol Biomed Life Sci 2002, 777:269-279.
20. Suzuki H., Higuchi T., Sawa K., et al. Endemic coast goitre in Hokkaido, Japan. Acta Endocrinol 1965, 50:161-176.
21. Zimmermann M.B., Jooste P.L., Mabapa N.S., et al. Vitamin A supplementation in iodine-deficient African children decreases thyrotropin stimulation of the thyroid and reduces the goiter rate. Am J Clin Nutr 2007, 86:1040-1044.
22. Ingenbleek Y. Vitamin A deficiency impairs the normal mannosylation, conformation and iodination of the thyroglobulin: a new etiological approach to endemic goiter. Experientia Suppl 1983, 44:264-297.
23. Zimmermann M.B. The influence of iron status on iodine utilization and thyroid function. Annu Rev Nutr 2006, 26:367-389.
24. Brauer V.F., Schweizer U., Köhrle J., et al. Selenium and goiter prevalence in borderline iodine sufficiency. Eur J Endocrinol 2006, 155:807-812.
25. Kralik A., Eder K., Kirchgessner M. Influence of zinc and selenium deficiency on parameters relating to thyroid hormone metabolism. Horm Metab Res 1996, 28:223-226.
26. Ruz M., Codoceo J., Galgani J., et al. Single and multiple selenium-zinc-iodine deficiencies affect rat thyroid metabolism and ultrastructure. J Nutr 1999, 129:174-180.
27. Wada L., King J.C. Effect of low zinc intakes on basal metabolic rate, thyroid hormones and protein utilization in adult men. J Nutr 1986, 116:1045-1053.
28. Brucker-Davis F. Environmental disrupters of thyroid hormone action. Encyclopedia of hormones 2003, 535-537. Elsevier-Academic Press, New York. H.L. Henry, A.N. Norman (Eds.).
29. Lindsay R.H., Hill J.B., Gaitan E., et al. Antithyroid effects of coal-derived pollutants. J Toxicol Environ Health 1992, 37:467-481.
30. Braverman L.E. Clinical studies of exposure to perchlorate in the United States. Thyroid 2007, 17:819-822.
31. Laurberg P., Nøhr S.B., Pedersen K.M., et al. Iodine nutrition in breast-fed infants is impaired by maternal smoking. J Clin Endocrinol Metab 2004, 89:181-187.
32. Bignell G.R., Canzian F., Shayeghi M., et al. Familial nontoxic multi-nodular thyroid goiter locus maps to chromosome 14q but does not account for familial nonmedullary thyroid cancer. Am J Hum Genet 1997, 61(5):1123-1130.
33. Brix T.H., Kyvik K.O., Hegedüs L. Major role of genes in the etiology of simple goiter in females: a population-based twin study. J Clin Endocrinol Metab 1999, 84(9):3071-3075.
34. Neumann S., Willgerodt H., Ackermann F., et al. Linkage of familial euthyroid goiter to the multinodular goiter-1 locus and exclusion of the candidate genes thyroglobulin, thyroperoxidase, and Na+/I- symporter. J Clin Endocrinol Metab 1999, 84:3750-3756.
35. Capon F., Tacconelli A., Giardina E., et al. Mapping a dominant form of multinodular goiter to chromosome Xp22. Am J Hum Genet 2000, 67:1004-1007.
36. Brix T.H., Hegedüs L. Genetic and environmental factors in the aetiology of simple goitre. Ann Med 2000, 32:153-156.
37. Takahashi T., Nozaki J., Komatsu M., et al. A new locus for a dominant form of multinodular goiter on 3q26.1-q26.3. Biochem Biophys Res Commun 2001, 284:650-654.
38. Bayer Y., Neumann S., Meyer B., et al. Genome-wide linkage analysis reveals evidence for four new susceptibility loci for familial euthyroid goiter. J Clin Endocrinol Metab 2004, 89:4044-4052.
39. Krohn K., Führer D., Bayer Y., et al. Molecular pathogenesis of euthyroid and toxic multinodular goiter. Endocr Rev 2005, 26:504-524.
40. Ngan E.S., Lang B.H., Liu T., et al. A germline mutation (A339V) in thyroid transcription factor-1 (TITF-1/NKX2.1) in patients with multinodular goiter and papillary thyroid carcinoma. J Natl Cancer Inst 2009, 101:162-175.
41. Corral M., Perez R., Sanchez I., et al. Thyroglobulin gene point mutation associated with non-endemic simple goiter. Lancet 1993, 341:462-464.
42. González-Sarmiento R., Corral J., Mories M.T., et al. Monoallelic deletion in the 5' region of the thyroglobulin gene as a cause of sporadic nonendemic simple goiter. Thyroid 2001, 11:789-793.
43. Rubio I.G., Medeiros-Neto G. Mutations in the thyroglobulin gene and its relevance to thyroid disorders. Curr Opin Endocrinol Diabetes Obes 2009, 16:373-378.
44. Pardo V., Vono-Toniolo J., Rubio I.G., et al. The p.A2215D thyroglobulin gene mutation leads to deficient synthesis and secretion of the mutated protein and congenital hypothyroidism with wide phenotype variation. J Clin Endocrinol Metab 2009, 94:2938-2944.
45. Bonnema S.J., Bennedbaek F.N., Ladenson P.W., et al. Management of the nontoxic multinodular goiter: a North American survey. J Clin Endocrinol Metab 2002, 87:112-117.
46. Bonnema S.J., Bennedbaek F.N., Wiersinga W.M., et al. Management of the nontoxic multinodular goitre: a European questionnaire study. Clin Endocrinol (Oxf) 2000, 53(1):5-12.
47. Samuels M.H. Evaluation and treatment of sporadic nontoxic goiter-some answers and more questions. J Clin Endocrinol Metab 2001, 86:994-997. [editorial].
48. Abdel Rahim A.A., Ahmed M.E., Hassan M.A. Respiratory complications after thyroidectomy and the need for tracheostomy in patients with a large goitre. Br J Surg 1999, 86:88-90.
49. Torre G., Borgonovo G., Amato A., et al. Surgical management of substernal goiter: analysis of 237 patients. Am Surg 1995, 61:826-831.
50. Vadasz P., Kotsis L. Surgical aspects of 175 mediastinal goiters. Eur J Cardiothorac Surg 1998, 14:393-397.
51. Röjdmark J., Järhult J. High long term recurrence rate after subtotal thyroidectomy for nodular goitre. Eur J Surg 1995, 161:725-727.
52. Hegedüs L., Nygaard B., Hansen J.M. Is routine thyroxine treatment to hinder postoperative recurrence of nontoxic goiter justified?. J Clin Endocrinol Metab 1999, 84:756-760.
53. Berghout A., Wiersinga W.M., Drexhage H.A., et al. The long-term outcome of thyroidectomy for sporadic non-toxic goitre. Clin Endocrinol (Oxf) 1989, 31:193-199.
54. Miccoli P., Antonelli A., Iacconi P., et al. Prospective, randomized, double-blind study about effectiveness of levothyroxine suppressive therapy in prevention of recurrence after operation: result at the third year of follow-up. Surgery 1993, 114:1097-1101. [discussion: 1101-2].
55. Hussain M., Hisham A.N. Total thyroidectomy: the procedure of choice for toxic goitre. Asian J Surg 2008, 31:59-62.
56. Riju R., Jadhav S., Kanthaswamy R., et al. Is total thyroidectomy justified in multinodular goitre. J Indian Med Assoc 2009, 107(4):223-225.
57. Cannon C.R., Lee R., Didlake R. Management of the substernal goiter: a team approach. J Miss State Med Assoc 2010, 51(7):179-182.
58. Albayral Y., Demiryilmaz I., Kaya Z., et al. Comparison of total thyroidectomy, bilateral subtotal thyroidectomy and Dunhill operations in the treatment of benign thyroid disorders. Minerva Chir 2011, 66(3):189-195.
59. Dogan L., Karaman N., Yilmaz K.B., et al. Total thyroidectomy for the surgical treatment of multinodular goiter. Surg Today 2011, 41(3):323-327.
60. Güllü S., Gürses M.A., Başkal N., et al. Suppressive therapy with levothyroxine for euthyroid diffuse and nodular goiter. Endocr J 1999, 46(1):221-226.
61. Lima N., Knobel M., Cavaliere H., et al. Levothyroxine suppressive therapy is partially effective in treating patients with benign, solid thyroid nodules and multinodular goiters. Thyroid 1997, 7:691-697.
62. Wesche M.F., Tiel-V Buul M.M., Lips P., et al. A randomized trial comparing levothyroxine with radioactive iodine in the treatment of sporadic nontoxic goiter. J Clin Endocrinol Metab 2001, 86:998-1005.
63. Papini E., Petrucci L., Guglielmi R., et al. Long-term changes in nodular goiter: a 5-year prospective randomized trial of levothyroxine suppressive therapy for benign cold thyroid nodules. J Clin Endocrinol Metab 1998, 83:780-783.
64. Cesareo R., Iozzino M., Isgrò M.A., et al. Short term effects of levothyroxine treatment in thyroid multinodular disease. Endocr J 2010, 57(9):803-809.
65. Zelmanovitz F., Genro S., Gross J.L. Suppressive therapy with levothyroxine for solitary thyroid nodules: a double-blind controlled clinical study and cumulative meta-analyses. J Clin Endocrinol Metab 1998, 83:3881-3885.
66. Grussendorf M., Reiners C., Paschke R., et al. Reduction of thyroid nodule volume by levothyroxine and iodine alone and in combination: a randomized, placebo-controlled trial. J Clin Endocrinol Metab 2011, 96:2786-2795.
67. Nielsen V.E., Bonnema S.J., Boel-Jørgensen H., et al. Stimulation with 0.3-mg recombinant human thyrotropin prior to iodine 131 therapy to improve the size reduction of benign nontoxic nodular goiter: a prospective randomized double-blind trial. Arch Intern Med 2006, 166(14):1476-1482.
68. Hegedüs L., Hansen B.M., Knudsen N., et al. Reduction of size of thyroid with radioactive iodine in multinodular non-toxic goitre. BMJ 1988, 297:661-662.
69. Bonnema S.J., Hegedüs L. A 30-year perspective on radioiodine therapy of benign nontoxic multinodular goiter. Curr Opin Endocrinol Diabetes Obes 2009, 16:379-384.
70. Silva M.N., Rubió I.G., Romão R., et al. Administration of a single dose of recombinant human thyrotrophin enhances the efficacy of radioiodine treatment of large compressive multinodular goitres. Clin Endocrinol (Oxf) 2004, 60:300-308.
71. Bonnema S.J., Nielsen V.E., Boel-Jørgensen H., et al. Improvement of goiter volume reduction after 0.3 mg recombinant human thyrotropin-stimulated radioiodine therapy in patients with a very large goiter: a double-blinded, randomized trial. J Clin Endocrinol Metab 2007, 92(9):3424-3428.
72. Medeiros-Neto G., Marui S., Knobel M. An outline concerning the potential use of recombinant human thyrotropin for improving radioiodine therapy of multinodular goiter. Endocrine 2008, 33:109-117.
73. Fast S., Nielsen V.E., Grupe P., et al. Optimizing 131I uptake after rhTSH stimulation in patients with nontoxic multinodular goiter: evidence from a prospective, randomized, double-blind study. J Nucl Med 2009, 50:732-737.
74. Fast S., Nielsen V.E., Bonnema S.J., et al. Time to reconsider nonsurgical therapy of benign non-toxic multinodular goitre: focus on recombinant human TSH augmented radioiodine therapy. Eur J Endocrinol 2009, 160:517-528.
75. Hegedüs L. Therapy: a new nonsurgical therapy option for benign thyroid nodules?. Nat Rev Endocrinol 2009, 5:476-478.
76. Romão R., Rubio I.G., Tomimori E.K., et al. High prevalence of side effects after recombinant human thyrotropin-stimulated radioiodine treatment with 30 mCi in patients with multinodular goiter and subclinical/clinical hyperthyroidism. Thyroid 2009, 19:945-951.
77. Cubas E.R., Paz-Filho G.J., Olandoski M., et al. Recombinant human TSH increases the efficacy of a fixed activity of radioiodine for treatment of multinodular goitre. Int J Clin Pract 2009, 63:583-590.
78. Ceccarelli C., Brozzi F., Bianchi F., et al. Role of the recombinant human TSH in the management of large euthyroid multinodular goiter: a new therapeutic option? Pros and cons. Minerva Endocrinol 2010, 35(3):161-171.
79. Fast S, Nielsen VE, Bonnema SJ, et al. Recombinant human TSH (rh TSH) augmented radioiodine treatment of benign multinodular goitre. Available at: 2010. Accessed November 7, 2011. http://www.hotthyroidology.com/.
80. Fast S., Nielsen V.E., Bonnema S.J., et al. Dose-dependent acute effects of recombinant human TSH (rhTSH) on thyroid size and function: comparison of 0.1, 0.3 and 0.9 mg of rhTSH. Clin Endocrinol (Oxf) 2010, 72:411-416.
81. Ceccarelli C., Antonangeli L., Brozzi F., et al. Radioiodine 131I treatment for large nodular goiter: recombinant human thyrotropin allows the reduction of radioiodine 131I activity to be administered in patients with low uptake. Thyroid 2011, 21:759-764.
82. Graf H., Fast S., Pacini F., et al. Modified-release recombinant human TSH (MRrhTSH) augments the effect of (131)I therapy in benign multinodular goiter: results from a multicenter international, randomized, placebo-controlled study. J Clin Endocrinol Metab 2011, 96:1368-1376.
83. Fast S., Bonnema S.J., Hegedüs L. Radioiodine therapy of benign non-toxic goitre: potential role of recombinant human TSH. Ann Endocrinol (Paris) 2011, 72(2):129-135.